A merchant bank operates investment and advisory platforms while also being an active investor on a principal basis. The firm invests in a variety of industries including media & entertainment, renewable energy, digital assets, consumer, and life sciences. The firm recently had an initial close on their inaugural life sciences fund, and is actively seeking early-stage investment opportunities in Series A to C rounds. Initial check sizes will be between $3-7M with reserved follow-on investments. The firm focuses US-based companies, and will consider those based in Europe, Israel, and other geographies who are looking to expand operations or relocate to the US. 
 
Within life sciences, the firm will consider opportunities in therapeutics, medical devices, and diagnostics. The firm does not invest in digital health or healthcare IT-based solutions. The firm is opportunistic and will consider all types of novel modalities, technologies, and disease areas that address a high unmet medical need. While the firm does invest in early-stage companies, the firm will expect companies to have a lead asset and indication in place, demonstrating strong pre-clinical data and be close to IND filing. 
 
The firm seeks to work with companies with a committed, full-time management team in place. The firm typically does not lead investment rounds and prefers to syndicate with other likeminded investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

As a corporate venture arm of a leading global service provider, the fund is open to investing in anywhere from seed to IPO financing rounds. Initial investment size can vary and follow-on investment is possible. The firm primarily seeks opportunities in the US, and is open to China and Europe as well. The firm does not lead rounds and prefers companies with a lead investor in place.  Depending on the investment size and deal terms, the fund may consider an observer seat or board seat. The firm makes equity investments only and does not have an equity-for-service model.  

Separately from the corporate venture arm, the parent company also runs a program for which it collaborates with over 25 partners, such as accelerators, seed/venture capital firms, incubators, and other similar programs to provide startups various tools and resources to accelerate biologics and vaccine development, including credits for the firm’s technology platforms. Startups must be an active participant or referred by a Program Partner to be eligible. 
 
The firm will consider a wide range of biotech assets, from antibody drug, protein therapeutics, vaccines, DNA and mRNA drugs. The fund is also open to orphan drugs. One type of asset that the fund does not consider cell and gene therapy. 
 
The firm does not lead rounds therefore would only invest when a lead investor is secured. The fund is open to working with new or first time founders but hopes to see that the team has a good supportive network. The fund is interested in working with founders who are open to advice and suggestions. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm based in Seattle, Washington is looking to make another 10 investments with its current fund. The fund primarily invests in Series A, but is open to Seed and Series B. The typical check size is between $250K – $2M, dependent on the stage of investment. The firm identifies themselves as very involved investors and will not invest until they see a clear path through which they can add value to the company. The firm has a strong diversity lens and looks for diverse teams including women and individuals of different backgrounds. The firm invests in USA based companies. 

 
The firm will invest in therapeutics, diagnostics, medical devices, and digital health. The fund is particularly interested in companies targeting health related issues impacting underserved populations and geographies, such as diabetes, cancer, femtech, and cardiovascular health. The fund looks for therapeutics companies to be within 6 months of submission for phase 1 trials. The fund will look at medical device companies within 6 months of 510(k) approval. The fund also requires that there is an MVP and customer attraction but does not require there to be revenue. Similarly with diagnostics, the firm requires an MVP but does not require revenue. The fund does require digital health companies to have revenue. 
 
The firm prefers to work with management teams with prior experience with startups or within the industry, but is not a firm requirement. The firm will lead or co-invest. The firm requires a board seat when leading rounds. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A firm based in Europe raised a second fund with €60M under management for Pre-Seed, Seed, and Series A investments. The fund is backed by a majority of private investors with the support of a number of institutional investors such as European Investment Fund (EIF). The firm invests €1-2M as a seed investment in the form of equity or convertible notes to help companies advance into preclinical proof of concept and can continue investing up to €6M. If additional funds are needed, the firm seeks co-investments from the strong network of investors they have in Europe. The firm is looking for investments across Europe. 
 
The firm invests in the biotech sector, exclusively in the drug development space, and with a preference for Advanced Therapies and Synthetic Biology. The firm has an interest in cutting edge technology, and it specializes in tech transfer opportunities. The firm is agnostic indication-wise and will invest in projects in preclinical stage that have reached an in vivo proof of concept in an animal model relevant for the disease for which the therapy is being developed. 
 
The firm looks for companies with a scientific founder, and preferably a C-Level executive with a track record in biotech or pharmaceutical companies. The firm prefers to lead or co-lead in Seed stage therapeutics companies and will seek a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An investment firm headquarters in China with offices in the US focuses on early-stage investments in life science and healthcare sectors. The firm typically engages in pre-A to series B financing rounds, with initial investment sizes ranges from $500k to $8M, and potential for follow-on investments. The firm looks for opportunities mostly in Europe, and in the US and UK as well. The firm is open to both leading and co-investing. 
 
The firm is interested in therapeutics, medical devices and diagnostics. The firm is open to looking at digital health, AI -related companies but has not invested in one yet. The firm is opportunistic in terms of subsectors and indications. Some areas of interest include immunology, immuno-oncology, CNS disorders and kidney-related diseases. For therapeutics, the firm is open to looking at companies from phase I to beyond, particularly those with proof of concepts or clinical data validating their technologies. For medical devices and diagnostics, the firm tends to look for more mature companies, with product or prototype ready and as well as plans for regulatory approvals. 
 
The firm does not have specific requirements for a company’s management team but prefers to work with founding teams that have entrepreneurial experiences previously. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

The firm is a Private Equity firm that was founded in 2001 and based in Paris, France. The firm controls €550 million in assets under management across institutional and retail funds. The firm typically makes equity investments ranging from €1 to €20 million over the lifetime of the investment and is also highly interested in the in-licensing of early stage assets and technologies. The firm has an 8 year period to exit and plans to make 2-3 investments over the next 6-9 months. The firm invests in companies located throughout Europe with a focus on France.  For in-licensing opportunities the firm is willing to look globally. 
 
The firm Is currently most interested in companies developing Therapeutics and Medical Devices and is also considering investments in Diagnostics. In the Therapeutics space the firm is open in terms of indication but has strong interest in immunotherapy, vaccines, and biologics subsectors though they are also open to small molecules. In the medical device space the firm has a strong preference for investing in cardiovascular devices but considers other opportunities as well. The firm looks to invest in very early stages of company development generally when lead assets are preclinical and technologies are still in development. 
 
The firm looks to make seed investments as well as being involved in the formulation of a company. The firm is not likely to invest in companies that have already received significant institutional financing and looks to lead investments rounds. The firm also participates in spin-offs from larger companies that are looking to sell non-strategic assets.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A single family office is an active investor in early-stage companies. The firm is very flexible in terms of investment size they are generally looking to invest a minimum of $.5 million per round, depending upon size of round and estimated capital call. The firm prefers A round and later stage companies. Pre-A interest depends upon technology stage. Currently, the firm is investing only in companies based in North America. 
 
The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Devices, and Diagnostics Sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. Currently, of particular interest are optical or sound-based technologies, devices that supplant drug use, orthopedics, gene/nucleic acid-based therapies, immuno-oncology and therapies correcting or treating  loss of senses. 
 
The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor. The firm is looking for companies that have already raised seed financing and have received allowance of claims by the USPTO. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.